# ZAI Lab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zai-lab

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.zailaboratory.com
- Total disclosed funding: $160M
- Latest round: Series C (Jun 28, 2017)
- Investors on record: 9

## About

Founded in 2014 and based in Shanghai, China, ZAI Lab Limited operates as a biopharmaceutical company that discovers and develops therapeutics to address oncology, autoimmune and infectious diseases, with an R&D center in Shanghai, clinical and regulatory offices in Beijing, manufacturing and R&D facilities in Suzhou, commercial offices in Hong Kong, Taiwan, Guangzhou, and U.S. As of March 31, 2022, ZAI Lab has more than 1,999 employees. In September 2020, it was listed on the Hong Kong Stock Exchange with stock code 9688. In September 2017, it completed USD 172 million NASDAQ IPO. The founder and CEO, Samantha Du, used to serve on the boards at Sequoia Capital China and led four healthcare investments. The company focused on bringing medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. The products include ZEJULA (niraparib), Tumor Treating Fields (TTFields) therapy, QINLOCK (ripretinib), and NUZYRA (omadacycline). The clinical development team currently manages more than 50 ongoing or planned clinical trials. The company will use the funds to complete clinical trials and advance new drug candidates, support new business development and licensing opportunities, and expand commercialization operations. In December 2024, ZAI Lab Limited raised CNY 300 million in venture debt funding from new investor Bank of Communications.

## Funding rounds

- Series C, Jun 28, 2017, $30M — OrbiMed Advisors, Vivo Capital, Qiming Venture Partners, Rock Springs Capital, Cormorant Asset Management
- Series B, Jan 8, 2016, $100M — OrbiMed Advisors, Hong Shan, Qiming Venture Partners, TF Capital, Advantech Capital
- Series A, Apr 1, 2015 — Qiming Venture Partners
- Series A, Aug 27, 2014, $30M — Kleiner Perkins, Hong Shan, Qiming Venture Partners, TF Capital

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A
- Hong Shan — Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- TF Capital — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Rock Springs Capital — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C